Scarica l'app Stockscreener
0.00
100.00%
-9.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Fibrogen Inc Borsa (FGEN) Ultime notizie
FibroGen Inc stock (US3156631046): volatility after Nasdaq delisting and Kynbio merger plans - AD HOC NEWS
KYNTRA BIO (KYNB) CEO Thane Wettig purchases 2,800 shares at $7.09 - Stock Titan
Armistice Capital (FGEN) reports 400,000-share, 9.88% position (May 2026) - Stock Titan
Health News Roundup: FibroGen's neuromuscular disorder therapy fails late-stage study; Merck sues US government to halt Medicare drug price negotiation and more - Devdiscourse
FibroGen, Inc. (FGEN) - Minichart
Kyntra Bio (Nasdaq: KYNB) Q1 2026 results show higher revenue, ongoing R&D spend - Stock Titan
Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances - AD HOC NEWS
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc.FGEN - TMX Newsfile
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc.FGEN - TMX Newsfile
Kyntra Bio (NASDAQ: FGEN) details 2026 virtual meeting and pay vote - Stock Titan
FibroGen Shareholder Alert - TMX Newsfile
FibroGen Inc stock (US3156631046): Is its hypoxia-inducible factor focus still the real test for bio - AD HOC NEWS
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq Moves: Can FibroGen Inc sustain its profitability2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Retail Trends: What is the target price for FibroGen Inc stock2026 Summary & Verified Short-Term Plans - baoquankhu1.vn
Sentiment Review: Will FibroGen Inc benefit from government policy2026 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
FibroGen Inc stock: What investors need to know now - AD HOC NEWS
Kyntra Bio CEO to webcast April 13 presentation at Needham event - Stock Titan
Aug Sentiment: Is FibroGen Inc stock a value trap2026 Momentum Check & Reliable Momentum Entry Alerts - baoquankhu1.vn
FibroGen Inc Stock: Biotech Innovator Focused on Hypoxia Pathways and Oncology for Long-Term Investo - AD HOC NEWS
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Setups: What is the long term forecast for FibroGen Inc stock2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Aug Macro: Can FibroGen Inc sustain its profitability2026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
Rate Cut: What is the long term forecast for FibroGen Inc stock2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
FibroGen Inc stock leads biotech gains on China asset sale and FDA update amid Q4 earnings scrutiny - AD HOC NEWS
FibroGen Inc stock faces renewed scrutiny amid expanding interstitial lung disease pipeline competit - AD HOC NEWS
If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
FibroGen Inc stock faces scrutiny ahead of delayed Q4 earnings release amid pipeline pressures - AD HOC NEWS
Revenue of Fibrogen from 2020 to 2024 - Statista
Breakout Watch: Is FibroGen Inc stock a value trapPortfolio Update Report & Smart Investment Allocation Insights - baoquankhu1.vn
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
FibroGen Q4 2025 earnings preview - MSN
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - gurufocus.com
Bull Run: What is the long term forecast for FibroGen Inc stock2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Gains Report: Is FibroGen Inc stock a value trap2025 Market WrapUp & Long Hold Capital Preservation Plans - baoquankhu1.vn
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca - MSN
Quarterly Earnings: What is the target price for FibroGen Inc stockJobs Report & Safe Capital Investment Plans - baoquankhu1.vn
FGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Breakouts: Can FibroGen Inc be the next market leaderJuly 2025 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Earnings Risk: Is FibroGen Inc stock a value trapWeekly Stock Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
FibroGen (FGEN) Delisted: What’s Really Left for Shareholders? - AD HOC NEWS
Analyst Upgrade: Why is FibroGen Inc stock going up2025 Performance Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
KYNB Stock Price, News & Analysis - Stock Titan
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
1.27%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):